Trend
DailyDowntrend (confirmed)
4 hourBullish
1 hourLeaning Bearish
15 minBearish
5 minConsolidating
Daily trend turns up above $272.08
Key levels
Resistance$181.66
Resistance$170.49
Support$156.00
Support$144.73
Latest news & SEC filings
AnalystBarclays kept its Overweight rating on Alnylam (ALNY) and lowered its price target to $380 from $450.
AnalystTruist Securities downgraded Alnylam (ALNY) to Hold from Buy and lowered its price target to $225 from $315.
All ALNY news →Alnylam discovers and sells medicines built on RNA interference, a natural cellular process it uses to switch off genes that drive disease. Its marketed drugs address transthyretin amyloidosis, a rare liver disorder called acute hepatic porphyria, and a kidney condition involving oxalate buildup. Partners Novartis and Sanofi sell its cholesterol and hemophilia therapies. The business spans the United States, Europe, Japan and other markets, and it also runs a large pipeline of experimental treatments.
Based on the company's 10-K filed Feb 12, 2026.
Nasdaq · Healthcare
SEPT Low Target
$220.00
SEPT Mid Target
$319.00
SEPT High Target
$455.00
Analyst Consensus
$319.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ALNY.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$278.38
40
Moat Score
NARROW
6/9
Piotroski Score
3.2
Altman Z-Score
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
SELLING
0 buys / 2 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SUPRAN BRYAN | officer | Sale | 1,758 | $399K | Oct 2, 2026 |
| Greenstreet Yvonne | director officer | Buy | 107 | - | Sep 19, 2026 |
| PYOTT DAVID E I | director | Buy | 3,830 | - | Jun 1, 2026 |
| PYOTT DAVID E I | director | Sale | 921 | $274K | Jun 1, 2026 |
| PYOTT DAVID E I | director | Sale | 1,175 | $351K | Jun 1, 2026 |
| PYOTT DAVID E I | director | Sale | 1,222 | $366K | Jun 1, 2026 |
| PYOTT DAVID E I | director | Sale | 495 | $149K | Jun 1, 2026 |
| PYOTT DAVID E I | director | Sale | 17 | $5K | Jun 1, 2026 |
| Sigal Charles Elliott | director | Buy | 671 | - | May 20, 2026 |
| SCHULMAN AMY W | director | Buy | 838 | - | May 20, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
65.2%
3yr Revenue CAGR
53.0%
EPS Growth YoY
206.88%
FCF Growth YoY
1192.7%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for ALNY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:01:33 | $158.00 | 75,000 | $$11.8M | SELL |
| 15:57:30 | $158.04 | 1,600 | $$253K | SELL |
| 15:56:43 | $157.87 | 1,069 | $$169K | BUY |
| 15:47:22 | $157.95 | 4,926 | $$778K | BUY |
| 15:44:57 | $158.01 | 1,247 | $$197K | SELL |
5 dark pool trades shown · $$13.2M preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for ALNY, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $155 | Nov 20 | 8 | $$2550 | 3 | SWEEP |
| PUT | $135 | Mar 19 | 127 | $$2640 | 3 | SWEEP |
| CALL | $160 | Nov 20 | 8 | $$3600 | 8 | SWEEP |
| CALL | $160 | Nov 20 | 8 | $$1800 | 4 | SWEEP |
| CALL | $160 | Nov 20 | 8 | $$1350 | 3 | SWEEP |
5 options trades shown · 80% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for ALNY. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup — $ALNY (ALNYLAM PHARMACEUTICALS, INC.) Price: $264.38 | Zone: $246.48 — $269.94 Conviction: HIGH | Analyst upside: +31.5% Near resistance (76% of range) — breakout watch. Strong positive...
Join 3,500+ traders discussing ALNY in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for ALNYLAM PHARMACEUTICALS, INC. (ALNY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ALNYLAM PHARMACEUTICALS, INC. (ALNY) is at $157.87, down 1.24% (-$1.98) at the Nov 12, 2026 close.
Latest ALNY news — Nov 2, 2026: Barclays kept its Overweight rating on Alnylam (ALNY) and lowered its price target to $380 from $450. · Nov 2, 2026: Truist Securities downgraded Alnylam (ALNY) to Hold from Buy and lowered its price target to $225 from $315.
The average analyst price target for ALNY is $319.00, ranging from $220 to $455, based on 16 analysts. Latest: Barclays maintains on Nov 2, 2026.
Analyst ratings for ALNY: 1 Buy, 36 Hold, 2 Sell — consensus Hold.
ALNY last reported on Oct 29, 2026: EPS $16.26 vs $1.66 expected — a beat of 879.5%.
ALNY trades at a P/E of 8.6 vs a Healthcare average of 18.4.
ALNY does not currently pay a dividend.
Support: $156.00, $144.73. Resistance: $170.49, $181.66, $197.81.
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
Nov 2, 2026: Barclays kept its Overweight rating on Alnylam (ALNY) and lowered its price target to $380 from $450. · Nov 2, 2026: Truist Securities downgraded Alnylam (ALNY) to Hold from Buy and lowered its price target to $225 from $315.